We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Kinaxo Enters in to an Agreement with AstraZeneca
News

Kinaxo Enters in to an Agreement with AstraZeneca

Kinaxo Enters in to an Agreement with AstraZeneca
News

Kinaxo Enters in to an Agreement with AstraZeneca

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Kinaxo Enters in to an Agreement with AstraZeneca"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Kinaxo will employ high-end mass spectrometry-based technologies to quantitatively analyze posttranslational protein modifications on a proteome-wide scale. Since protein modifications play pivotal roles in many cellular processes (e.g. cell death or DNA repair) such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets. Financial details of the agreement were not disclosed.


Dr. Henrik Daub, CTO at Kinaxo commented: “Posttranslational modifications and their regulation are key factors in understanding cellular behavior and molecular drug action. We are delighted to apply our expertise to support AstraZeneca’s research in such highly promising fields of investigation. This collaboration further strengthens Kinaxo’s position as a preferred technology partner for global pharmaceutical companies.”

Advertisement